Methods for treating muscular dystrophy with casimersen

A technology for muscular dystrophy and Duchenne muscular nutrition, applied in gene therapy, pharmaceutical formulations, muscular system diseases, etc., can solve the problem of limited pharmacological options for DMD

Pending Publication Date: 2021-11-16
SAREPTA THERAPEUTICS INC
View PDF25 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, despite these successes, the pharmacological options available for the treatment of DMD are limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating muscular dystrophy with casimersen
  • Methods for treating muscular dystrophy with casimersen
  • Methods for treating muscular dystrophy with casimersen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0182] Example 1: ESSENCE

[0183] ClinicalTrials.gov Identifier: NCT02500381

[0184] The primary objective of this study was to evaluate the efficacy of Coximosen (SRP-4045) and Golodirsen (SRP-4053) compared to placebo with the ability to skip exon 45 and exon 53, respectively. Efficacy in Duchenne muscular dystrophy (DMD) patients with out-of-frame deletion mutations.

[0185] Research Type: Intervention

[0186] Study Design: Allocation: Random

[0187] Intervention Mode: Parallel Assignment

[0188] Shielding: Quadruple (Participant, Care Provider, Investigator, Outcome Assessor)

[0189] Primary Purpose: Healing

[0190] Title: A double-blind, placebo-controlled, multicenter study with an open-label extension to evaluate the efficacy and safety of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy

[0191] Materials and methods

[0192] Quasimosen (also known as SRP-4045) is a PMO of the chemical structure described herein and is supplied by...

Embodiment 2

[0232] The primary objectives of the study are to assess the safety and tolerability of simoxan and to evaluate the pharmacokinetics (PK ).

[0233] method

[0234] A multicenter, randomized, double-blind, placebo-controlled, dose-titration, phase 1 / 2 study enrolled patients with advanced DMD and a confirmed mutation suitable for exon 45 skipping.

[0235] During double-blind dose titration, patients were randomized (2:1) to receive quasimosen or placebo for approximately 12 weeks. Patients randomized to receive quasimosen received 4 escalating dose levels (4, 10, 20, and 30 mg / kg), administered once weekly by intravenous (IV) infusion, for ≥2 weeks at each dose level. Following the double-blind dose-titration period, the safety and efficacy of once-weekly 30 mg / kg quasimoxan was assessed in an open-label extension period of up to an additional 132 weeks.

[0236] Patient: Eligibility

[0237] Eligible patients were males aged 7-21 years with a clinical diagnosis of DMD, w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
strengthaaaaaaaaaa
diameteraaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present disclosure provides, among other things, improved compositions and methods for treating muscular dystrophy. For example, the disclosure provides methods for treating Duchenne muscular dystrophy patients having a mutation in the DMD gene that is amenable to exon 45 skipping by administering an effective amount of casimersen.

Description

[0001] related application [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 825,573, filed March 28, 2019, and U.S. Provisional Application No. 62 / 902,518, filed September 19, 2019. The entire teaching of the above application is incorporated by reference in its entirety. technical field [0003] The present invention relates to improved methods for treating muscular dystrophy in a patient. It also provides compositions suitable for promoting exon 45 skipping in the human dystrophin gene. Background technique [0004] In various genetic diseases, the impact of genetic mutations on the final expression of genes can be modulated by the process of targeted exon skipping during splicing. In cases where normally functional proteins are terminated prematurely due to mutations in them, the means of restoring the production of some functional proteins by antisense technology has been shown to be possible by intervening in the splicing process, if...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7125A61P21/00A61P43/00A61K9/00
CPCA61K31/7125A61P21/00A61P43/00A61K9/0019A61K47/26A61K48/00A61P21/04
Inventor E·M·凯
Owner SAREPTA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap